The FDA has issued a warning about numerous adverse events, including hospitalizations, stemming from dosing errors and overdoses of compounded semaglutide injectable products, underscoring the risks posed by non-FDA-approved variations. These errors often stem from patients incorrectly measuring and self-administering doses and healthcare providers miscalculating doses. Also Read: Novo Nordisk’s Ozempic Reduces Smoking-Related Health Interventions In Diabetic Patients, Study Finds. Novo Nordisk A/S’s (NYSE:NVO) semaglutide belongs to a class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists. There are currently three FDA-approved semaglutide products: Wegovy injection is a single-dose prefilled pen that delivers a preset dose for once-weekly dosing. Ozempic injection is available as multiple-dose prefilled pens for ...